Gastroesophageal reflux disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Influence of cytochrome P450 2C19 genetic polymorphism and dosage of rabeprazole on accuracy of proton-pump inhibitor testing in Chinese patients with gastroesophageal reflux disease.
|
17559380 |
2007 |
Gastroesophageal reflux disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These results suggest that azeloprazole sodium is useful for treating gastroesophageal reflux disease in all CYP2C19 genotypes.
|
29193126 |
2018 |
Gastroesophageal reflux disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
PubMed and other electronic databases were systematically searched up to August 2014 using the following terms: "GERD and CYP2C19", "esophagitis and CYP2C19", and "non-erosive reflux disease and CYP2C19."
|
26580676 |
2016 |
Gastroesophageal reflux disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Cure rates for GERD depended significantly on the CYP2C19 genotype status, as well as the grade of GERD before treatment.
|
12386647 |
2002 |
Gastroesophageal reflux disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These CYP2C19 genotype-dependent differences in pharmacokinetics and pharmacodynamics of PPIs influence the cure rates for the gastro-esophageal reflux disease and H. pylori infection by PPI-based therapies.
|
15988117 |
2005 |
Gastroesophageal reflux disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, the clinical usefulness of CYP2C19 genotype testing in GERD therapy should be verified in clinical studies.
|
22873740 |
2012 |
Gastroesophageal reflux disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In a second trial plasma levels of esomeprazole and corresponding CYP2C19 and CYP3A4 metabolites (5-hydroxyomeprazole and omeprazole sulfone) were monitored in 10 CYP2C19 wild-type patients with GERD after the first and last doses (day 7) of 40 mg esomeprazole daily to calculate metabolic ratios.
|
16338278 |
2005 |
Gastroesophageal reflux disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Children ages 6-17 years old with clinician-diagnosed asthma and mild GERD symptoms will submit a saliva sample for CYP2C19 genotyping.
|
30659924 |
2019 |
Gastroesophageal reflux disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Likewise, limited data suggest that proton pump inhibitors-induced healing rates in gastro-oesophageal reflux disease are apparently higher in poor metabolizers/het extensive metabolizers than in extensive metabolizers of CYP2C19.
|
15245569 |
2004 |
Gastroesophageal reflux disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In erosive esophagitis patients, the FSSG scores of the CYP2C19 rapid metabolizers (RMs) were significantly higher than the scores of the poor metabolizers and intermediate metabolizers (total scores: 16.7 ± 8.6 <i>vs</i> 7.8 ± 5.4, <i>P</i> < 0.05; acid reflux-related symptom scores: 12 ± 1.9 <i>vs</i> 2.5 ± 0.8, <i>P</i> < 0.005).
|
28373773 |
2017 |
Gastroesophageal reflux disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The AUC of rabeprazole depended on the CYP2C19 genotypes in Japanese GERD patients; however, the intragastric pH elevation was independent of CYP2C19 genotypes, which is consistent with the CYP2C19 genotype-independent healing efficacy of erosive lesions by rabeprazole.
|
17725594 |
2008 |
Gastroesophageal reflux disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To determine if the CYP2C19 genotype is associated with clinical effectiveness of proton-pump inhibitors during GERD therapy.
|
12823155 |
2003 |
Gastroesophageal reflux disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We hypothesized that pH probe acid exposure outcomes associate with CYP2C19*17 alleles among children with clinical concern for GERD.
|
28884817 |
2018 |
Gastroesophageal reflux disease
|
0.100 |
Biomarker
|
disease |
LHGDN |
These CYP2C19 genotypic differences in pharmacokinetics and pharmacodynamics of PPIs influence the healing and eradication rates for the gastro-esophageal reflux disease and Helicobacter pylori infection by PPI-based regimens.
|
17924835 |
2007 |
Gastroesophageal reflux disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Herein, we discuss the role of CYP2C19 and its relation to PPI therapy, particularly in those with GERD.
|
30050742 |
2018 |
Gastroesophageal reflux disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
These CYP2C19 genotypic differences in pharmacokinetics and pharmacodynamics of PPIs influence the healing and eradication rates for the gastro-esophageal reflux disease and Helicobacter pylori infection by PPI-based regimens.
|
17924835 |
2007 |
Gastroesophageal reflux disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CYP2C19 genetic polymorphism also affects the therapeutic outcome of gastroesophageal reflux disease (GERD), reflux oesophagitis and duodenal ulcers.
|
18765869 |
2008 |
Gastroesophageal reflux disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The CYP2C19 genotyping test would be useful for determining the optimal dose of a PPI for maintenance therapy of GERD.
|
19259653 |
2009 |
Gastroesophageal reflux disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These CYP2C19 genotype-dependent differences in pharmacokinetics and pharmacodynamics of PPIs are reflected in the cure rates for gastroesophageal reflux disease and Helicobacter pylori infection with PPI-based therapies.
|
15016609 |
2004 |